Catalent, Inc.

Pharmaceuticals, Biotechnology and Life Sciences

Targets set1.5°C

SBTI ID

40012804

Informations générales

Localisation

United States of America

Northern America

Secteur d'activité

Pharmaceuticals, Biotechnology and Life Sciences

Type d'organisation

Corporate

Dernière mise à jour

25/01/2024

Objectifs à court terme (Near-Term)
Engagement de réduction des émissions à horizon FY2030

Statut

Targets set

Classification

1.5°C

Année cible

FY2030

Progression vers l'objectif0%
2015 (année de référence)FY2030
Description complète des objectifs

Catalent commits to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from an FY2022 base year. Catalent also commits to reduce absolute scope 3 GHG emissions from fuel- and energy-related activites, and employee commuting 25% within the same timeframe. Catalent further commits that 70% of its suppliers by emissions, covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by FY2028.

Business Ambition 1.5°C

Statut

BA1.5 member

Date d'engagement

22/07/2021

Classification détaillée

The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C

Identifiants

ISIN

US1488061029

LEI

549300HALRZ339MSTH85

Source : Science Based Targets initiative | Données publiques